KalVista Pharmaceuticals, Inc.
KALV · NASDAQ
4/30/2025 | 4/30/2024 | 4/30/2023 | 4/30/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $86,167 | $0 | $0 |
| Gross Profit | $0 | -$86,167 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $71,709 | $86,167 | $80,276 | $70,167 |
| G&A Expenses | $116,286 | $54,278 | $30,595 | $26,446 |
| SG&A Expenses | $116,286 | $54,278 | $30,595 | $26,446 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$86,167 | $0 | $0 |
| Operating Expenses | $187,995 | $54,278 | $110,871 | $96,613 |
| Operating Income | -$187,995 | -$140,445 | -$110,871 | -$96,613 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $7,943 | $5,349 | $17,964 | $14,274 |
| Pre-Tax Income | -$180,052 | -$135,096 | -$92,907 | -$82,339 |
| Tax Expense | $3,392 | -$8,452 | $0 | $0 |
| Net Income | -$183,444 | -$126,644 | -$92,907 | -$82,339 |
| % Margin | – | – | – | – |
| EPS | -3.69 | -3.44 | -3.33 | -3.36 |
| % Growth | -7.3% | -3.3% | 0.9% | – |
| EPS Diluted | -3.69 | -3.44 | -3.33 | -3.36 |
| Weighted Avg Shares Out | 49,653 | 36,787 | 27,891 | 24,473 |
| Weighted Avg Shares Out Dil | 49,653 | 36,787 | 27,891 | 24,473 |
| Supplemental Information | – | – | – | – |
| Interest Income | $6,435 | $0 | $2,232 | $1,090 |
| Interest Expense | $5,785 | $0 | $0 | $0 |
| Depreciation & Amortization | $941 | $816 | $718 | $564 |
| EBITDA | -$173,326 | -$134,280 | -$94,368 | -$80,746 |
| % Margin | – | – | – | – |